US20200009202A1 - Bacterial composition and its use - Google Patents
Bacterial composition and its use Download PDFInfo
- Publication number
- US20200009202A1 US20200009202A1 US16/298,035 US201916298035A US2020009202A1 US 20200009202 A1 US20200009202 A1 US 20200009202A1 US 201916298035 A US201916298035 A US 201916298035A US 2020009202 A1 US2020009202 A1 US 2020009202A1
- Authority
- US
- United States
- Prior art keywords
- pta
- lactobacillus
- composition
- bacteria
- bacterial composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 230000001580 bacterial effect Effects 0.000 title claims abstract description 30
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 29
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 29
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 25
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 25
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 25
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 24
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 24
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 22
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 20
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 20
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 16
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 16
- 241000894006 Bacteria Species 0.000 claims description 42
- 230000000529 probiotic effect Effects 0.000 claims description 16
- 239000006041 probiotic Substances 0.000 claims description 14
- 235000018291 probiotics Nutrition 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 9
- 210000000987 immune system Anatomy 0.000 claims description 7
- 230000013632 homeostatic process Effects 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 12
- 102000004127 Cytokines Human genes 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 16
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 206010009887 colitis Diseases 0.000 description 11
- 235000013305 food Nutrition 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 102000015696 Interleukins Human genes 0.000 description 7
- 108010063738 Interleukins Proteins 0.000 description 7
- 108010019160 Pancreatin Proteins 0.000 description 7
- 229940047122 interleukins Drugs 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 229940055695 pancreatin Drugs 0.000 description 7
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 102000057297 Pepsin A Human genes 0.000 description 6
- 108090000284 Pepsin A Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 229940111202 pepsin Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000003833 bile salt Substances 0.000 description 5
- 229940093761 bile salts Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 4
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 4
- 229940044627 gamma-interferon Drugs 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000012891 Ringer solution Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000005095 gastrointestinal system Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003092 anti-cytokine Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- -1 Decane Hexadecane acetate Chloroform Chemical compound 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000013435 necrotic lesion Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C12R1/01—
-
- C12R1/225—
-
- C12R1/23—
-
- C12R1/25—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Definitions
- the aim of the present invention is to satisfy these requirements.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The subject or the present invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802. An other subject of the invention is an immunomodulation method comprising the step of using the at least one strain selected from the preceding group.
Description
- The subject of the present invent on is a bacterial composition, in immunomodulation method and the use of this composition. Immunomodulation is the capacity to improve the global immune functions either in healthy or in pathologic situations.
- Among bacteria, some have a positive influence on the immune system of the intestinal medium, in particular lactic acid bacteria and bifidobacteria, and are termed “probiotic” bacteria or strains.
- The expression probiotic bacteria or strains is understood to mean a strain which, when ingested live, exerts a beneficial effect on the host by having an action on the balance of the intestinal flora. These probiotic strains have the capacity to survive following passage across the upper part of the digestive tube. They are non-pathogenic, non-toxic and exert a beneficial action on health through in one hand their ecological interactions with the resident flora of the digestive tract and in the other hand their ability to positively influence immune system, through their effects onto the GALT (gut associated immune tissue). According to the probiotic definition, those bacteria when given in sufficient numbers have the capacity to transit alive all along the gut. There they become part of the resident flora for the period of administration. The so called colonisation (or transcient colonisation) allow the probiotic bacteria to exert beneficial effect, such as repression of potentially pathogen micro-organisms on the flora and interactions with the gut immune system.
- The probiotic strains most widely used, in particular in dairy products, are mainly bacteria and yeasts, of the following genera Lactobacillus spp, Streptococcus spp, Enterococcus app and Bifidobacterium spp and Saccharomyces spp. Among the probiotic effects reported for those bacteria, one can cite for example, improvement of lactose tolerance, prevention and or treatment of gastrointestinal and urogenital infections, reduction of some cancers, decrease of blood cholesterol. However, it should be highlighted that not all the individual strains from the genera described above have those effects, but only some carefully selected strains do.
- Thus in order to satisfy the requirements for performant probiotic strains, it has become necessary to select strains or a mixture thereof which is efficient and which allow stimulation of the immune system (immunomodulation).
- Accordingly, the problem which the present invention proposes to solve is to provide a bacterial composition having probiotic properties.
- The aim of the present invention is to satisfy these requirements.
- For this purpose, the present invention provides a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis a PTA-4802.
- Another subject of the invention is an immunomodulation method.
- The subject of the invention is also a food or pharmaceutical composition comprising the bacterial compositions described above.
- Another subject of the invention is also the use of this composition in the preparation of a carrier administered to humans or to animals for a therapeutic or prophylactic purpose in the gastrointestinal system.
- The composition of the invention has the advantage of providing unquestionable virtues which enrich the range of available strains.
- Such a composition is particularly advantageous when it is administered to humans or to animals for a therapeutic or prophylactic purpose in the gastrointestinal system, in particular in the reduction of inflammatory and/or allergic reactions.
- The advantage of the present invention is also to preserve all its properties when it is incorporated into a pharmaceutically acceptable carrier or into a food product.
- Other advantages and characteristics of the present invention will emerge more clearly on reading the description and the examples given purely by way of illustration and without limitation, which follow.
- First of all, the subject of the invention is a bacterial composition having immunomodulation properties comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
- The Lactobacillus acidophilus used according to the invention is a Gram-positive strain.
- Advantageously, it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
- The Lactobacillus acidophilus used according to the invention may also produce a bacteriocin, lactacin, which is active against other microorganisms.
- Preferably, it is a Lactobacillus acidophilus exhibiting good resistance to pepsin, under acidic pH conditions (about at least 73% of the bacteria are still alive after 40 minutes of treatment).
- More particularly, the Lactobacillus acidophilus used according to the invention exhibits a very good resistance to pancreatin (at least 100% of the bacteria are still alive after 40 minutes of treatment).
- Advantageously, the Lactobacillus acidophilus used according to the invention exhibits good tolerance to bile salts.
- Preferably, a Lactobacillus acidophilus described as being “hydrophobic”, that is to say which exhibits a high affinity for hydrophobic organic solvents, polar or not polar, such as for example n-decane, chloroform, hexadecane or xylene, will be used.
- The Lactobacillus acidophilus used according to the invention can induce the production of cytokines. This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC). Among the cytokines induced during this test, there may be mentioned interleukins 10 (IL10), γ-interferon (γ-IFN) and tumour necrosis factor α (TNFα). On the other hand, the Lactobacillus acidophilus used according to the invention induces little or no secretion of interleukins 12 (IL12) using this same test.
- The Lactobacillus acidophilus used according to the invention is Lactobacillus acidophilus PTA-4797. This Lactobacillus acidophilus strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4797.
- One embodiment of the composition according to the invention is a bacterial composition comprising Lactobacillus acidophilus PTA-4797.
- The composition made of probiotic bacteria according to the invention may also comprise at least one Lactobacillus plantarum strain.
- The Lactobacillus plantarum strain used according to the invention is preferably a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
- Preferably, it is a Lactobacillus plantarum which is resistant to pepsin under acidic pH conditions (about at least 951 of the bacteria are still alive after 40 minutes of treatment).
- More particularly, the Lactobacillus plantarum used according to the invention exhibits good resistance to pancreatin (about at least 79% of the bacteria are still alive after 40 minutes of treatment).
- Advantageously, the Lactobacillus plantarum used according to the invention exhibits good resistance to bile salts.
- The Lactobacillus plantarum used according to the invention can induce the production of cytokines. This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC). Among the cytokines induced during this test, there may be mentioned interleukins 10 (IL10), γ-interferon (γ-IFN) and tumour necrosis factor α (TNFα). On the other hand, the Lactobacillus plantarum used according to the invention induces little or no secretion of interleukins 12 (IL12) using this same test.
- The Lactobacillus plantarum used according to the invention is Lactobacillus plantarum PTA-4799. This Lactobacillus plantarum strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4799.
- One embodiment of the composition according to the invention is a bacterial composition comprising Lactobacillus plantarum PTA-4799.
- The composition made of probiotic bacteria according to the invention may also comprise at least one Lactobacillus salivarius strain.
- The Lactobacillus salivarius strain used according to the invention is a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
- More particularly, the Lactobacillus salivarius used according to the invention exhibits good resistance to pancreatin (at least 100% of the bacteria are still alive after 40 minutes of treatment).
- The Lactobacillus salivarius used according to the invention can induce the secretion of cytokines. This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC). Among the cytokines induced during this test, there may be mentioned interleukins 10 (IL10) and tumour necrosis factor α (TNFα). On the other hand, the Lactobacillus salivarius used according to the invention induces little or no secretion of interleukin 12 (IL12) and γ-interferon (γ-IFN) using this same test.
- The Lactobacillus salivarius used according to the invention is Lactobacillus salivarius PTA-4800. This Lactobacillus salivarius strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4800.
- One embodiment of the composition according to the invention is a bacterial composition comprising Lactobacillus salivarius PTA-4800.
- The composition made of probiotic bacteria according to the invention may also comprise at least one Lactobacillus paracasei strain.
- The Lactobacillus paracasei used according to the invention is a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a homofermentative metabolism giving rise to the production of lactic acid.
- Preferably, it is a Lactobacillus paracasei exhibiting poor resistance to pepsin, under acidic pH conditions (about at least 17.5% of the bacteria are still alive after 40 minutes of treatment).
- More particularly, the Lactobacillus paracasei used according to the invention exhibits very good resistance to pancreatin (about at least 100% of the bacteria are still alive after 40 minutes of treatment).
- Advantageously, the Lactobacillus paracasei used according to the invention exhibits good tolerance to bile salts.
- The Lactobacillus paracasei used according to the invention can induce the production of cytokines. This detection of the induction of cytokines was made by means of a test for in vitro stimulation of isolated peripheral blood mononuclear cells (PBMC). Among the cytokines induced during this test, there may be mentioned interleukins 10 (IL10), γ-interferon (γ-IFN) and tumour necrosis factor α (TNFα). On the other hand, the Lactobacillus paracasei used according to the invention induces little or no secretion of interleukins 12 (IL12) using this same test.
- The Lactobacillus paracasei used according to the invention is Lactobacillus paracasei PTA-4798. This Lactobacillus paracasei strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number PTA-4798.
- One embodiment of the composition according to the invention is a bacterial composition comprising Lactobacillus paracasei PTA-4798.
- The composition made of probiotic bacteria according to the invention may also comprises at least one Bifidobacterium bifidum strain.
- The Bifidobacterium bifidum strain used according to the invention is a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a heterofermentative metabolism giving rise to the production of lactic acid and acetic acid.
- The Bifidobacterium bifidum used according to the invention is Bifidobacterium bifidum PTA-4801. This Bifidobacterium bifidum strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number ATCC PTA-4801.
- One embodiment of the composition according to the invention is a bacterial composition comprising Bifidobacterium bifidum PTA-4801.
- The composition made of probiotic bacteria according to the invention may also comprises at least one Bifidobacterium lactis strain.
- The Bifidobacterium lactis strain used according to the invention is a Gram-positive strain. Advantageously, it is a catalase-negative strain, with a heterofermentative metabolism giving rise to the production of lactic acid and acetic acid.
- The Bifidobacterium lactis used according to the invention is Bifidobacterium lactis PTA-4802. This Bifidobacterium lactis strain was deposited according to the Treaty of Budapest at the American Type Culture Collection where it is recorded under the deposit number ATCC PTA-4801.
- One embodiment of the composition according to the invention is a bacterial composition comprising Bifidobacterium lactis PTA-4801.
- Another embodiment of the composition according to the invention is a bacterial composition comprising at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, and Bifidobacterium lactis PTA-4802.
- More particularly, the composition according to the invention may comprise at least 2 strains selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
- More particularly, the composition according to the invention may comprise 3 strains selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
- Preferably, the composition according to the invention may comprise a blend of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium lactis PTA-4802 and Bifidobacterium bifidum PTA-4801.
- The composition according to the invention may be used in the form of a bacterial suspension, before or after freezing, or of a freeze-dried powder. Indeed, regardless of the form used, the composition may be frozen.
- The relative proportion of each bacterium in the composition can vary in large limit for example from 1/99 to 99/1 in the case there is at least 2 strains.
- The composition according to the invention may comprise from 106 to 1011 CFU of bacteria/g of composition, and more particularly from 108 to 1011 CFU of bacteria/g of composition. The term CFU means “colony forming units”. The expression gram of composition is understood to mean the food product or pharmaceutical preparation, and preferably 109 to 1011 CFU/g if in a freeze-dried form.
- The composition according to the invention is useful for the treatment, the primary prevention or the recurrence, and also the prevention and/or the reduction of inflammatory bowel disease.
- The bacterial composition according to the invention is also useful for maintaining the homeostasis of the immune system.
- The bacterial composition according to the invention is also useful for the prevention and/or the reduction of allergenicity.
- The bacterial composition according to the invention is also useful as immunoadjuvent.
- An other subject of the invention is also an immunomodulation method comprising the step of using at least one strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798, Bifidobacterium bifidum PTA-4801 and Bifidobacterium lactis PTA-4802.
- The composition according to the invention may be used in the form of a food product or pharmaceutical preparation.
- The expression pharmaceutical preparation is understood to mean for example a preparation in the form of capsule or tablet.
- The subject of the invention is also a food, dietary supplement or pharmaceutical composition comprising the bacterial composition described above.
- Preferably, the food composition comprising the composition according to the invention is a food supplements, a beverage product or a milk base powder.
- More particularly, the food composition comprising the composition according to the invention is a dairy product.
- More preferably the food composition comprising the composition according to the invention is an infant formula.
- The food or pharmaceutical composition according to the invention may have immunomodulation properties.
- Another subject of the invention is also the use of this composition in the preparation of a carrier administered to humans or to animals for a therapeutic or prophylactic purpose in the gastrointestinal system.
- The invention provides also a pharmaceutical composition comprising the bacterial composition described above useful for the prevention of inflamatory bowel disease.
- The invention provides also a pharmaceutical composition comprising the bacterial composition described above useful for immunomodulation.
- The
FIGS. 1, 3 and 5 are schedules of injection. - The
FIGS. 2, 4 and 6 are Wallace and Ameho scores, and weight of loss. - Concrete but nonlimiting examples of the invention will now be described.
- 1/ PBMC Test:
- PBMC (Peripheral Blood Mononuclear Cells) are prepared by centrifugation from human blood, derived from known donors and is further purified on a Ficoll gradient. Cells are harvested, washed, (red blood cells removed) and counted.
- Bacteria are prepared according to standard conditions and counted by plating on agarose medium according to proper dilutions (10−7, 10−8, 10−9 in Ringer solution).
- Cells are washed 3 times and suspended (et non dissolved) in PBS buffer. A verifier par Dominique PBMC cells are stimulated for 48 hours with the bacteria (allow negative control with Phosphate Buffer Saline solution (PBS)) under appropriate conditions of CO2. Then the supernatant containing the cytokines is frozen at −20° C.
- Cytokines expression levels are determined by ELISA tests («Enzyme Linked immuno sorbent assay»). ELISA plates are coated with anti-cytokine antibody (overnight procedure) and the antibody is blocked with a surfactant, the tween 80.
- A proper standard is prepared for known concentrations of cytokines which will cover the detection range of 15.62 till 2000 pg/ml (incubate overnight). Perform the anti-cytokine detection and quantify with streptavidine reaction on substrate (10 mg dABTS/10 ml of citric acid buffer 0.1M, pH4.35/20 μl H2O2).
- Cytokines are either pro-inflammatory/Th1 (TNFα, IFNγ, IL12) or anti-inflammatory (IL10).
-
Strains IL-10 IL-12 IFN-γ TNF-α L. acidophilus PTA-4797 309 1970 27591 L. salivarius PTA-4800 6881 31 1148 23509 L. paracasei PTA-4798 300 31 921 14046 The values are pg/ml. - 2/ Preparation of a Composition Made of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799 and Bifidobacterium lactis PTA-4802:
- A blend of 3 strains is prepared containing Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, et Bifidobacterium lactis PTA-4802. This blend is named LAB.
- To show in vivo, the immuno modulation capacity of this blend according to the invention, animal test were performed aimed at decreasing the chemically induced gut inflammation of mice. Several models were set-up to mimic human inflammatory bowel diseases.
- In the first model, injections of 1 mg/mice of TNBS (trinitrobenzene sulfonic acid, which is a colitis inducing agent) on
days FIG. 1 . The intake of bacteria (LAB) on days −4 to −1, 6, 9, 13 and 19 will show macroscopic and histological effects, which are scored onday 22, according to standard scores (Wallace and Ameho respectively). - The results obtained (see
FIG. 2 ) clearly showed an improvement of the colitis symptoms evidenced by -
- reduction of the increase of the submucosa
- reduction of the inflammation
- less weight loss A second model of chronic colitis was also used (based on Camoglio et al., Eur J Immunol 2000), 2 mg/mice of TNBS injected by intra-rectal route on
days FIG. 3 . The intake of bacteria (LAB) on days −5 to −1, ondays 5 and 12 (FIG. 3 ) will show macroscopic and histological effects, which are scored onday 16, according to standard scores (Wallace and Ameho respectively).
- The results obtained clearly showed an improvement of the colitis symptoms evidenced (see
FIG. 4 ) by -
- absence of necrotic lesions
- reduction of the increase of the submucosa
- reduction of the inflammation
- A third acute model of mice colitis was also set up. 100 mg/kg mice of TNBS is injected on
day 0. This will evoke an acute colitis. The schedule of injection is drawn onFIG. 5 . The intake of Bifidobacterium lactis PTA-4802 or Lactobacillus plantarum PTA-4799 (107 bacteria/mouse) on days −5 to 0 show macroscopic and histological effects which are scored onday 2. - Clear macroscopic improvement of the colitis symptoms were evidenced for strains Bifidobacterium lactis PTA-4802 and Lactobacillus plantarum PTA-4799 (
FIG. 6 ). - In general all the TNBS-induced colitis models in mice show that feeding LAB to these mice significantly reduced the level of intestinal translocation of indigenous bacteria from the intestinal flora into mesenteric lymph nodes and spleen after the induction of colitis. In addition, no translocation of probiotic bacterial strains according to the invention was observed.
- 3/ Resistance to Pepsin
- The aim of this test is to evaluate the resistance of bacteria to the passage of the gastric barrier by determining the number of bacteria that survive after cultivation in the presence of a pepsin solution in acid environment. In short, 100 μl of a stock culture frozen at −80° C. is inoculated in 10 ml of MRS (Man Rogosa Sharp) culture medium and incubated overnight at 30° C. or 37° C. Then cells are washed 3 times in PBS at pH7 and the pellet is suspended in 1 ml PBS buffered and inoculated in 200 μl aliquots in 4 tubes with 1 ml of filtered pepsin solution at
pH 2 supplemented with 300 μl of NaCl (0.5%). Cell count is performed on 100 μl aliquots taken from the tubes incubated at T0 (time of inoculation), T0+5 min; T0+23 min; T0+40 min; T0+60 min and dilutions are plated on MRS (100 μl) of 10−5, 10−6 et 10−7 (consecutive 10 fold dilutions made in 1 ml Ringer solution). The percentage surviving bacteria is calculated for each incubation time from the reading of the dilution series. - All results displayed in the tables are the result of triplicate experiments
-
Strains 5 min 20 min 40 min 60 min L. acidophilus PTA-4797 91 74 73 55 L. plantarum PTA-4799 100 100 95 42 L. salivarius PTA-4800 100 66 23 7 L. paracasei PTA-4798 100 17.5 17.5 1.5 Results as % of survival compared to T = 0. - 4/ Resistance to Pancreatin
- The aim of this test is to evaluate the resistance of bacteria to the passage of the intestinal transit by determining the number of bacteria that survive after cultivation in the presence of a pancreatin solution in basic environment. In short, 100 μl of a stock culture frozen at −80° C. is inoculated in 10 ml of MRS (Man Rogosa Sharp) culture medium and incubated overnight at 30° C. or 37° C. Cells are washed 3 times in PBS at pH7 and the pellet is suspended in 1 ml PBS buffered and inoculated in 200 μl aliquots in 4 tubes with 1 ml of filtered pancreatin solution at pH 8 supplemented with 300 μl of NaCl (0.5%). Cell count is performed on 100 μl aliquots taken from the tubes incubated at T0 (time of inoculation), T0+5 min; T0+20 min; T0+40 min; T0+60 min; T0+120 min and dilutions are plated on MRS (100 μl) of 10−5, 10−6, 10−7 (consecutive 10 fold dilutions made in 1 ml Ringer solution). The percentage surviving bacteria is calculated for each incubation time from the reading of the dilution series. All results displayed in the tables are the result of triplicate experiments.
-
Strains 5 min 20 min 40 min 60 min 120 min L. acidophilus 83 100 100 170 170 PTA-4797 L. salivarius 100 115 152 158 155 PTA-4800 L. plantarum 86 72 79 84 87 PTA-4799 L. paracasei 65 100 100 100 100 PTA-4798 Results as % of survival compared to T = 0. - 5/ Resistance to Bile Salts
- The experimental is procedure is as follows. 100 μl culture of a stock frozen at −80° C. is inoculated in 10 ml de milieu de culture MRS (Man Rogosa Sharp) and incubated overnight at 30° C. or 37° C. The optical density (CD) is measured and a dilution is prepared (OD=0.05 to 0.1) in two bottles. One of the culture bottles is supplemented with a 0.3% solution of bile salts (750 μl of a filtered 12% solution) and incubated at the correct temperature. The OD is regularly measured until a OD of 0.3 is reached in the control bottle without bile salts. At that point the OD of the supplemented bottle is measured and one starts to measure the time needed to obtain the same OD of 0.3. The resistance of the strain is therefore evaluated as the delay in growth time.
- Results are coded as sensitive (0; more than 60 minutes), tolerant (1; between 15 and 60 minutes) or resistant (2; less than 15 minutes).
- All results displayed in the tables are the result of triplicate experiments
-
Strains Resistance L. acidophilus PTA-4797 1 L. plantarum PTA-4799 2 L. paracasei PTA-4798 2 - 6/ Hydrophobicity and Affinity for Organic Solvents
- The MATS test as described by Rosdenberg et al., 1980 (FEMS Microbiol.
Letters 9; 29-33) has been used. In short the test measures (grown overnight under normal in vitro growth conditions and washed twice in PBS) the hydrophobicity and polarity of the bacterial cell wall, based on the repartition (measured by optical density) of the bacteria into two non mixable liquid aqueous phases and five respective solvents. Growth medium is MRS (Man Rogosa Sharp) and the aqueous phase is a buffer as PBS. The solvents were decane, hexadecane, ethyl acetate, chloroform and xylene. - The affinity for chloroform, acid solvent, reflects the electron donor nature of the bacterium (basic reaction)
- The affinity for Ethyl Acetate, basic solvent, reflects the electron acceptor nature of the bacterium (acid reaction)
- The affinity for apolar solvents (decane, hexadecane, xylene) reflects the hydrophobic character of the bacterium.
- Possibly a high hydrophobicity is related to the presence of glycoproteins on the cell wall surface, while a low hydrophobicity could be linked to the presence of polysaccharides on the cell wall surface.
-
% D′HDROPHOBICITY=(1−A/A0)×100 with -
- AO: Original OD at 540 nm (set more or less at OD=0.6 in PBS)
- A: Optical density of aqueous phase (for 1 ml) after vortexing and stabilisation period
-
Ethyl Strains Decane Hexadecane acetate Chloroform Xylene L. acidophilus 81.9 60.4 44.2 90.3 90.9 PTA-4797 L. salivarius 23.02 38.17 2.25 79.28 51.18 PTA-4800 L. paracasei 36.5 37.4 28.8 45.2 30.6 PTA-4798 L. plantarum 25.3 25.6 28.7 28.8 21.9 PTA-4799
Claims (11)
1-21. (canceled)
22. A method for preventing or reducing inflammatory bowel syndrome, maintaining the homeostasis of the immune system, or reducing the allergenicity of a human or animal in need thereof, wherein the method comprises administering to the human or animal an effective amount of a bacterial composition comprising Bifidobacterium bifidum PTA-4801.
23. A method according to claim 22 , wherein the method is a method for preventing or reducing inflammatory bowel syndrome in the human or animal.
24. A method according to claim 22 , wherein the method is a method for maintaining the homeostasis of the immune system of the human or animal.
25. A method according to claim 22 , wherein the method is a method for reducing the allergenicity of the human or animal.
26. A method according to claim 22 , wherein the Bifidobacterium bifidum PTA-4801 is the only probiotic bacteria in the bacterial composition.
27. A method according to claim 22 , wherein the bacterial composition further comprises at least one additional strain selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798 and Bifidobacterium lactis PTA-4802.
28. A method according to claim 22 , wherein the bacterial composition further comprises at least two additional strains selected from the group consisting of Lactobacillus acidophilus PTA-4797, Lactobacillus plantarum PTA-4799, Lactobacillus salivarius PTA-4800, Lactobacillus paracasei PTA-4798 and Bifidobacterium lactis PTA-4802.
29. A method according to claim 22 , wherein the bacterial composition comprises from 106 to 1011 CFU of bacteria/g of composition.
30. A method according to claim 22 , wherein the bacterial composition comprises from 108 to 1011 CFU of bacteria/g of composition.
31. A method according to claim 22 , wherein the method comprises administering to a human in need thereof an effective amount of a bacterial composition comprising Bifidobacterium bifidum PTA-4801.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/298,035 US20200009202A1 (en) | 2002-12-05 | 2019-03-11 | Bacterial composition and its use |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/310,549 US7179460B2 (en) | 2002-12-05 | 2002-12-05 | Bacterial composition and its use |
| US11/594,543 US7740838B2 (en) | 2002-12-05 | 2006-11-08 | Bacterial composition and its use |
| US12/778,509 US8071086B2 (en) | 2002-12-05 | 2010-05-12 | Bacterial composition and its use |
| US13/283,778 US20120135036A1 (en) | 2002-12-05 | 2011-10-28 | Bacterial composition and its use |
| US14/493,710 US20150079041A1 (en) | 2002-12-05 | 2014-09-23 | Bacterial composition and its use |
| US15/457,205 US20180028581A1 (en) | 2002-12-05 | 2017-03-13 | Bacterial composition and its use |
| US16/298,035 US20200009202A1 (en) | 2002-12-05 | 2019-03-11 | Bacterial composition and its use |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/457,205 Continuation US20180028581A1 (en) | 2002-12-05 | 2017-03-13 | Bacterial composition and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20200009202A1 true US20200009202A1 (en) | 2020-01-09 |
Family
ID=38194038
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/594,543 Expired - Lifetime US7740838B2 (en) | 2002-12-05 | 2006-11-08 | Bacterial composition and its use |
| US11/594,542 Abandoned US20070148147A1 (en) | 2002-12-05 | 2006-11-08 | Bacterial composition and its use |
| US12/778,509 Expired - Fee Related US8071086B2 (en) | 2002-12-05 | 2010-05-12 | Bacterial composition and its use |
| US13/283,778 Abandoned US20120135036A1 (en) | 2002-12-05 | 2011-10-28 | Bacterial composition and its use |
| US14/493,710 Abandoned US20150079041A1 (en) | 2002-12-05 | 2014-09-23 | Bacterial composition and its use |
| US15/457,205 Abandoned US20180028581A1 (en) | 2002-12-05 | 2017-03-13 | Bacterial composition and its use |
| US16/298,035 Abandoned US20200009202A1 (en) | 2002-12-05 | 2019-03-11 | Bacterial composition and its use |
Family Applications Before (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/594,543 Expired - Lifetime US7740838B2 (en) | 2002-12-05 | 2006-11-08 | Bacterial composition and its use |
| US11/594,542 Abandoned US20070148147A1 (en) | 2002-12-05 | 2006-11-08 | Bacterial composition and its use |
| US12/778,509 Expired - Fee Related US8071086B2 (en) | 2002-12-05 | 2010-05-12 | Bacterial composition and its use |
| US13/283,778 Abandoned US20120135036A1 (en) | 2002-12-05 | 2011-10-28 | Bacterial composition and its use |
| US14/493,710 Abandoned US20150079041A1 (en) | 2002-12-05 | 2014-09-23 | Bacterial composition and its use |
| US15/457,205 Abandoned US20180028581A1 (en) | 2002-12-05 | 2017-03-13 | Bacterial composition and its use |
Country Status (1)
| Country | Link |
|---|---|
| US (7) | US7740838B2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100203026A1 (en) * | 2007-07-25 | 2010-08-12 | Campina Nederland Holding B.V. | Probiotics for inducing satiety and/or satiation |
| CA2702293C (en) * | 2007-10-11 | 2016-08-02 | Danisco A/S | Probiotics for use in relieving symptoms associated with gastrointestinal disorders |
| US20110189149A1 (en) * | 2008-06-20 | 2011-08-04 | Remy Burcelin | New Uses of Lactic Acid Bacteria and Bifidobacteria |
| KR101075557B1 (en) * | 2008-12-03 | 2011-10-20 | 씨제이제일제당 (주) | Novel Lactobacillus plantarum and compositions comprising the same |
| KR101075558B1 (en) * | 2008-12-03 | 2011-10-20 | 씨제이제일제당 (주) | Novel Lactobacillus plantarum and compositions comprising the same |
| KR101255050B1 (en) | 2009-07-14 | 2013-04-16 | 씨제이제일제당 (주) | Novel lactobacillus plantarum and compositions comprising the same |
| KR101486999B1 (en) | 2009-07-22 | 2015-01-28 | 씨제이제일제당 주식회사 | Novel Lactobacillus plantarum and compositions comprising same |
| TW201106957A (en) * | 2009-08-31 | 2011-03-01 | Synbio Tech Inc | The new strain of Lactobacillus plantarum LP28 and its use in treating allergy |
| KR101178217B1 (en) | 2009-10-28 | 2012-09-07 | 씨제이제일제당 (주) | Novel lactobacillus plantarum and compositions comprising the same |
| WO2011059332A2 (en) | 2009-11-16 | 2011-05-19 | Stichting Top Institute Food And Nutrition | Improved immunomodulation by probiotics |
| US9113653B2 (en) | 2011-08-19 | 2015-08-25 | Steven J Maranz | Methods of administering probiotic organisms that synthesize carotenoid compounds in situ to enhance human health and nutrition |
| CN104694409B (en) * | 2013-12-06 | 2017-11-17 | 深圳华大基因科技有限公司 | Lactobacillus plantarum and application thereof |
| US11617771B2 (en) | 2016-12-15 | 2023-04-04 | The Regents Of The University Of California | Oral composition comprising lactic acid bacteria for regulating immune responses and methods related thereto |
| CN107058159B (en) * | 2016-12-29 | 2021-06-08 | 石家庄君乐宝乳业有限公司 | Lactobacillus plantarum JMCC0017 with good viability in milk beverage, its screening method and application |
| CN108969513B (en) * | 2018-09-12 | 2021-07-13 | 大理大学 | Establishment and application of an animal model of ulcerative colitis with liver stagnation and spleen deficiency |
| CN111235070B (en) * | 2020-03-18 | 2022-03-08 | 河北农业大学 | Breast milk infant source lactobacillus plantarum BF _15 and application thereof |
| CN112063565B (en) * | 2020-09-23 | 2022-04-12 | 山东环亿生物科技有限公司 | Inactivated lactobacillus agent and preparation method and application thereof |
| US20250082694A1 (en) * | 2021-07-22 | 2025-03-13 | International N&H Denmark Aps | Probiotics for use in boosting the immune system |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2031586C1 (en) * | 1993-02-05 | 1995-03-27 | Тамара Георгиевна Извекова | Biologically active product of sour milk and method for its production |
| US6241983B1 (en) * | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
| US5858356A (en) * | 1995-12-21 | 1999-01-12 | Abbott Laboratories | Lactobacillus acidophilus to inhibit cryptosporidiosis in mammals |
| US6033691A (en) * | 1996-06-13 | 2000-03-07 | Sancor Cooperativas Unidas Limitada | Process for manufacturing a biologically active fermented milk product and product obtained by the process |
| WO1998042194A1 (en) * | 1997-03-24 | 1998-10-01 | Viva America Marketing, Inc. | Stabilized solid bacteria compositions |
| JP3430853B2 (en) * | 1997-04-11 | 2003-07-28 | 株式会社ゲン・コーポレーション | Preventive and therapeutic agents for gastritis, gastric ulcer and duodenal ulcer |
| AUPO758297A0 (en) * | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
| KR100406344B1 (en) * | 1997-08-21 | 2003-11-19 | 뉴질랜드 대어리 보오드 | Immunity enhancing lactic acid bacteria |
| ID29150A (en) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | USE OF LACTOBACILLUS SALIVARIUS |
| AU2001272369A1 (en) * | 2000-07-17 | 2002-01-30 | Chr. Hansen A/S | Methods and formultations with probiotic microorganisms and medicaments |
-
2006
- 2006-11-08 US US11/594,543 patent/US7740838B2/en not_active Expired - Lifetime
- 2006-11-08 US US11/594,542 patent/US20070148147A1/en not_active Abandoned
-
2010
- 2010-05-12 US US12/778,509 patent/US8071086B2/en not_active Expired - Fee Related
-
2011
- 2011-10-28 US US13/283,778 patent/US20120135036A1/en not_active Abandoned
-
2014
- 2014-09-23 US US14/493,710 patent/US20150079041A1/en not_active Abandoned
-
2017
- 2017-03-13 US US15/457,205 patent/US20180028581A1/en not_active Abandoned
-
2019
- 2019-03-11 US US16/298,035 patent/US20200009202A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7740838B2 (en) | 2010-06-22 |
| US20120135036A1 (en) | 2012-05-31 |
| US20150079041A1 (en) | 2015-03-19 |
| US20180028581A1 (en) | 2018-02-01 |
| US20100322964A1 (en) | 2010-12-23 |
| US20070148148A1 (en) | 2007-06-28 |
| US20070148147A1 (en) | 2007-06-28 |
| US8071086B2 (en) | 2011-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200009202A1 (en) | Bacterial composition and its use | |
| US20040110270A1 (en) | Bacterial composition and its use | |
| Servin | Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens | |
| Doron et al. | Probiotics: their role in the treatment and prevention of disease | |
| Fuller | Probiotics 2: applications and practical aspects | |
| CN100552016C (en) | Bifidobacterium for the treatment of inflammatory diseases | |
| Famularo et al. | Stimulation of immunity by probiotics | |
| IE80629B1 (en) | Lactic bacteria | |
| Tomičić et al. | Beneficial properties of probiotic yeast Saccharomyces boulardii | |
| US20070098705A1 (en) | Probiotic composition comprising at least two lactic acid bacterial strains which are able to clonise the gatrointestonal tracts in combination with having intestinal survival property, intestinal binding property, an infection protection property and fiber fermenting property | |
| Kalliomäki et al. | Positive interactions with the microbiota: probiotics | |
| EP2220210B1 (en) | Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect | |
| JP4308481B2 (en) | Antiallergic agent | |
| AU2007335423B2 (en) | IgA production promoter | |
| Fliss et al. | Biological control of human digestive microbiota using antimicrobial cultures and bacteriocins | |
| Abdel-Megeed | Therapeutic impact of probiotics in various aspects | |
| BG112471A (en) | Immunomodulating synbiotic composition | |
| Mandal | Study of Lactobacillus Isolates from Human Sources with regard to Their Beneficial Physiological Attributes | |
| Beccati | Investigations of prebiotics and of inter-and intra-molecular glycan-protein interactions | |
| Kalliomäki et al. | Positive Interactions with the Microbiota | |
| BG2759U1 (en) | Immunomoduling synbiotic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |